First human test of new Cancer-Fighting drug shows promise

NCT ID NCT04702737

Summary

This early-stage study tested the safety and initial effectiveness of an experimental drug called Tarlatamab (AMG 757) in men with advanced neuroendocrine prostate cancer. The trial involved 41 participants and aimed to find the safest and most effective dose for future studies. Researchers measured side effects and looked for early signs that the drug could help control the cancer.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Chris OBrien Lifehouse

    Camperdown, New South Wales, 2050, Australia

  • Community Health Network MD Anderson Cancer Center - North

    Indianapolis, Indiana, 46250, United States

  • Erasmus Medisch Centrum

    Rotterdam, 3015 GD, Netherlands

  • Gustave Roussy

    Villejuif, 94805, France

  • Hospital Clinic i Provincial de Barcelona

    Barcelona, Catalonia, 08036, Spain

  • Keio University Hospital

    Shinjuku-ku, Tokyo, 160-8582, Japan

  • Landeskrankenhaus Salzburg

    Salzburg, 5020, Austria

  • Mayo Clinic Arizona

    Phoenix, Arizona, 85054, United States

  • Medizinische Universitaet Graz

    Graz, 8036, Austria

  • Ordensklinikum Linz Elisabethinen

    Linz, 4020, Austria

  • Peter MacCallum Cancer Centre

    Melbourne, Victoria, 3000, Australia

  • Royal Marsden Hospital

    Sutton, SM2 5PT, United Kingdom

  • The Ohio State University

    Columbus, Ohio, 43210, United States

  • Universitair Ziekenhuis Gent

    Ghent, 9000, Belgium

  • University of California at San Francisco Helen Diller Family Comprehensive Cancer Center

    San Francisco, California, 94158, United States

  • University of Chicago

    Chicago, Illinois, 60637, United States

  • University of Texas MD Anderson Cancer Center

    Houston, Texas, 77030, United States

  • Wake Forest University Health Sciences

    Winston-Salem, North Carolina, 27103, United States

  • Washington University

    St Louis, Missouri, 63110-1093, United States

  • Weill Cornell Medical College

    New York, New York, 10021, United States

  • Winship Cancer Institute of Emory University

    Atlanta, Georgia, 30322, United States

Conditions

Explore the condition pages connected to this study.